Gepubliceerd op donderdag 16 juni 2005
Misbruik van recht
"The European Commission has fined Anglo-Swedish group AstraZeneca €60 million for misusing the patent system and the procedures for marketing pharmaceuticals to block or delay market entry for generic competitors to its ulcer drug Losec.
Competition Commissioner Neelie Kroes commented: “I fully support the need for innovative products to enjoy strong intellectual property protection so that companies can recoup their R & D expenditure and be rewarded for their innovative efforts. However, it is not for a dominant company but for the legislator to decide which period of protection is adequate." Lees meer